Every material Form 8-K Kailera Therapeutics, Inc. has filed with the SEC since May 26, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Kailera Therapeutics reported a third-quarter 2026 net loss of $95.7 million, up from $39.6 million in the same period of 2025, as research and development and general and administrative expenses rose sharply. The company reported cash, cash equivalents and marketable securities of $1,037.6 million as of September 30, 2026, which it expects to fund operations into mid-2028.
Q3 2026 R&D expenses were $84.7 million, up from $27.0 million a year earlier.
Q3 2026 general and administrative expenses were $21.7 million, up from $13.1 million.
Ribupatide oral global Phase 3 program is expected to begin in the first half of 2027, following an End-of-Phase 2 meeting with the U.S. FDA.
Cash of $1,037.6 million is expected to fund operations into mid-2028.
Kailera Therapeutics reported a second-quarter 2026 net loss of $111.3 million, up from $28.9 million a year earlier, as research and development expenses rose to $101.1 million from $19.5 million. The company had $1,171.8 million in cash, cash equivalents and marketable securities as of June 30, 2026, which it expects to fund operations into mid-2028. For shareholders, the filing shows a much larger loss driven by expanded clinical development, and the statement of operations reports no revenue.
Q2 2026 net loss was $111.3 million, compared with $28.9 million in Q2 2025.
R&D expenses were $101.1 million versus $19.5 million; G&A expenses were $20.3 million versus $11.1 million.
Cash, cash equivalents and marketable securities totaled $1,171.8 million as of June 30, 2026, with runway into mid-2028.
Ribupatide oral has an active U.S. FDA IND; global Phase 3 obesity trial initiation is planned for the first half of 2027.
Kailera Therapeutics reported a first-quarter 2026 net loss of $78.9 million, up from $18.0 million a year earlier, as research and development expenses rose to $70.9 million from $10.1 million. The company said its cash, cash equivalents and marketable securities of $581.9 million, plus $718.8 million in gross IPO proceeds, will fund operations into mid-2028, and the filing reports no revenue for the period.
Net loss was $78.9 million for the quarter ended March 31, 2026, compared with $18.0 million a year earlier.
R&D expenses were $70.9 million versus $10.1 million, a $60.7 million increase tied to product candidate development and related costs.
General and administrative expenses were $13.8 million versus $10.3 million.
Cash, cash equivalents and marketable securities totaled $581.9 million at March 31, 2026, and are expected to fund operations into mid-2028.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Kailera Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →